Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LENVATINIB Cause Multiple organ dysfunction syndrome? 51 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 51 reports of Multiple organ dysfunction syndrome have been filed in association with LENVATINIB (Lenvima). This represents 0.2% of all adverse event reports for LENVATINIB.

51
Reports of Multiple organ dysfunction syndrome with LENVATINIB
0.2%
of all LENVATINIB reports
41
Deaths
34
Hospitalizations

How Dangerous Is Multiple organ dysfunction syndrome From LENVATINIB?

Of the 51 reports, 41 (80.4%) resulted in death, 34 (66.7%) required hospitalization, and 11 (21.6%) were considered life-threatening.

Is Multiple organ dysfunction syndrome Listed in the Official Label?

Yes, Multiple organ dysfunction syndrome is listed as a known adverse reaction in the official FDA drug label for LENVATINIB.

What Other Side Effects Does LENVATINIB Cause?

Diarrhoea (4,262) Hypertension (4,152) Fatigue (3,603) Decreased appetite (3,257) Malignant neoplasm progression (2,929) Nausea (2,492) Blood pressure increased (2,228) Vomiting (1,962) Asthenia (1,643) Malaise (1,602)

What Other Drugs Cause Multiple organ dysfunction syndrome?

TACROLIMUS (1,847) CYCLOPHOSPHAMIDE (1,597) MYCOPHENOLATE MOFETIL (1,566) PREDNISONE (1,525) DEXAMETHASONE (1,355) METHOTREXATE (1,317) METHYLPREDNISOLONE (1,278) RITUXIMAB (1,188) PREDNISOLONE (1,154) CYCLOSPORINE (933)

Which LENVATINIB Alternatives Have Lower Multiple organ dysfunction syndrome Risk?

LENVATINIB vs LEPONEX LENVATINIB vs LERCANIDIPINE LENVATINIB vs LETAIRIS LENVATINIB vs LETERMOVIR LENVATINIB vs LETROZOLE

Related Pages

LENVATINIB Full Profile All Multiple organ dysfunction syndrome Reports All Drugs Causing Multiple organ dysfunction syndrome LENVATINIB Demographics